FDA approves Signatera CDx as a companion diagnostic in muscle-invasive bladder cancer

FDA launches Rare Disease Framework Initiative for drug development

FDA announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.

October 16, 2026

Vol.52 No.38

Cancer Policy

FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members

FDA is requesting nominations by Dec. 14 for voting members to serve on the Tobacco Products Scientific Advisory Committee.

October 16, 2026

Vol.52 No.38

Drugs & Targets

FDA approves atezolizumab + chemotherapy for stage 3 colon cancer

FDA approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair.

October 16, 2026

Vol.52 No.38

Drugs & Targets

FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease

FDA expanded the approved indication for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin to include patients with BCG-unresponsive NMIBC with papillary-only tumors.

October 16, 2026

Vol.52 No.38

Podcast

As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”

As the oncology community waits with bated breath for a possible FDA approval of GRAIL’s Galleri test, NCI Director Anthony Letai has a lot to say about multi-cancer detection tests—particularly Galleri.

October 14, 2026

Clinical Roundup

Urine test may improve bladder cancer diagnosis and guide treatment decision, Stanford-led study finds

A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose people with bladder cancer more accurately than current standard methods. The test also allows physicians to not only assess the cancer’s response to treatment but to predict whether immunotherapy or chemotherapy is likely to be most effective for each patient.

October 09, 2026

Vol.52 No.37

FDA approves Signatera CDx as a companion diagnostic in muscle-invasive bladder cancer

YOU MAY BE INTERESTED IN

FDA launches Rare Disease Framework Initiative for drug development

FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members

FDA approves atezolizumab + chemotherapy for stage 3 colon cancer

FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease

As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”

Urine test may improve bladder cancer diagnosis and guide treatment decision, Stanford-led study finds

Renew today!

Subscriber content

Never miss an issue!

Login